Drugs for Rare Diseases: Influence of Orphan Designation Status on Price

Eline Picavet, Marc Dooms, David Cassiman and Steven Simoens
Additional contact information
Eline Picavet: Research Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium
Marc Dooms: Hospital Pharmacy, University Hospital Leuven, Leuven, Belgium
David Cassiman: Department of Hepatology, University Hospital Leuven, Leuven, Belgium
Steven Simoens: Research Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, Belgium

Applied Health Economics and Health Policy, 2011, vol. 9, issue 4, pages 275-279

Keywords: Orphan-drugs; Pricing (search for similar items in EconPapers)
JEL-codes: C D I Z I1 I19 I18 I11 (search for similar items in EconPapers)
Date: 2011
References: Add references at CitEc
Citations Track citations by RSS feed

Downloads: (external link)
http://healtheconomics.adisonline.com/pt/re/ahe/pd ... -201109040-00006.pdf (application/pdf)
http://healtheconomics.adisonline.com/pt/re/ahe/fu ... -201109040-00006.htm (text/html)
Pay per view

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: http://EconPapers.repec.org/RePEc:wkh:aheahp:v:9:y:2011:i:4:p:275-279

Access Statistics for this article

Applied Health Economics and Health Policy is edited by Tim Wrightson

More articles in Applied Health Economics and Health Policy from Springer Healthcare | Adis
Series data maintained by Dave Dustin ().